A lack of consensus guidelines or a belief that current evidence does not support such guidelines might be justified if a clinician expresses a commitment to patient-centered care and shared decision making.
AMA J Ethics. 2018;20(11):E1007-1016. doi:
10.1001/amajethics.2018.1007.
When symptoms of polypharmacy are consistent with those of difficult-to-diagnose disorders, reliable determinations about which drugs are necessary is critical.
AMA J Ethics. 2018;20(12):E1133-1138. doi:
10.1001/amajethics.2018.1133.
Dr Ala Shaikhkhalil joins Ethics Talk to discuss her article, coauthored with Drs Ethan A. Mezoff and Hannah Hays: “Should Clinicians Prescribe Non-FDA Regulated Dietary Supplements When Caring for Children With Hypovitaminosis D?”
Before the late 20th century, overweight and obesity were not considered population-wide health risks, but the advent of weight loss drugs in the 1990s accelerated hypermedicalization via BMI use.
AMA J Ethics. 2023;25(7):E550-558. doi:
10.1001/amajethics.2023.550.
Watie White joins Ethics Talk to discuss his article, coauthored with Dr Regina Idoate, Aislinn C. Rookwood, Sophia A. Quintero, Shelby Larson, Dr Arturo Aceves, and Dr Keyonna M. King: “Lead Toxicity and Environmental Health Justice Stories in Black and White Woodcut Portraits.”